Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Subscriptions

Domiciliary exhaled nitric oxide and eosinophilic airway inflammation in adults with asthma

Catriona Ruth Nanda, Amisha Singapuri, Marcia Soares, William Monteiro, Salman Siddiqui, Sherif Gonem
European Respiratory Journal 2016 48: 242-244; DOI: 10.1183/13993003.02060-2015
Catriona Ruth Nanda
1Institute for Lung Health, Department of Infection, Immunity and Inflammation, University of Leicester, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Amisha Singapuri
1Institute for Lung Health, Department of Infection, Immunity and Inflammation, University of Leicester, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marcia Soares
1Institute for Lung Health, Department of Infection, Immunity and Inflammation, University of Leicester, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
William Monteiro
1Institute for Lung Health, Department of Infection, Immunity and Inflammation, University of Leicester, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Salman Siddiqui
1Institute for Lung Health, Department of Infection, Immunity and Inflammation, University of Leicester, UK
2Both authors contributed equally
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sherif Gonem
1Institute for Lung Health, Department of Infection, Immunity and Inflammation, University of Leicester, UK
2Both authors contributed equally
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: sg330@le.ac.uk
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Exhaled nitric oxide home monitoring is a promising surrogate marker of eosinophilic airway inflammation in asthma http://ow.ly/108ak4

To the Editor:

Sputum eosinophils are the gold standard measure of eosinophilic airway inflammation and there is strong evidence that titrating corticosteroid therapy to sputum eosinophils reduces the rate of asthma exacerbations [1]. However, this measurement is time consuming and requires specific technical expertise. Exhaled nitric oxide (FeNO) is a noninvasive surrogate marker of eosinophilic airway inflammation that may be measured using small portable devices. Studies of using FeNO to titrate therapy have yielded mixed results [2, 3]. However, it is possible that one-off clinic readings may not be the best method of utilising FeNO, and the home monitoring potential of FeNO has not yet been fully explored.

We aimed i) to determine the reliability and feasibility of FeNO home monitoring in adults with moderate-to-severe asthma and ii) to investigate the relationship between serial FeNO measurements and recognised biomarkers of eosinophilic airways disease in asthma, specifically sputum and blood eosinophil counts. We hypothesised that serial FeNO measurements would correlate more closely with other biomarkers of eosinophilic airways disease than one-off readings, and that there may be a temporal relationship between FeNO and other eosinophil markers.

In this pilot study we recruited 10 adults (age >18 years) with moderate-to-severe asthma (Global Initiative for Asthma treatment steps 3–5 [4]), diagnosed by a specialist asthma physician in a secondary care setting, according to British Thoracic Society guidelines [5]. The study was approved by the National Research Ethics Committee – East Midlands Leicester, and all participants gave their written informed consent. The participant group comprised five men and five women with a mean±sd age of 64±5 years. All participants were treated with inhaled corticosteroids (800–2000 μg per day beclometasone dipropionate equivalent) and long-acting β2-agonists. Six patients received maintenance low-dose prednisolone (5–15 mg per day). Mean±sd post-bronchodilator forced expiratory volume in 1 s (FEV1) (% pred) was 71.4±24.2 with mean±sd bronchodilator reversibility of 9.3±11.2%. A previous history of atopy was documented in three patients. Geometric mean (95% confidence interval) sputum eosinophil count was 6.1% (1.7–22.2%) and blood eosinophil count was 0.18×109 cells·L−1 (0.07–0.46×109 cells·L−1).

Participants were recruited during the period from December 2013 – April 2014. They were each provided with a NObreath FeNO monitor (Bedfont Scientific, Maidstone, UK) and carefully instructed in its use. Participants were provided with a paper diary and asked to record three morning FeNO readings on a daily basis over a 56-day period. Participants attended study visits twice-weekly, at which time daily diaries were retrieved, a blood sample was drawn for measurement of eosinophil count, and sputum induction was performed (or a spontaneous sample obtained) [6]. Sputum cell counts were performed by an experienced technician.

Eight out of ten participants completed the study and good quality data were obtained in each case. The median missing data rate for home-monitored FeNO was 7.1% (range 2.7–14.3%). Home-monitored FeNO was repeatable, with a median intraclass correlation coefficient of triplicate measurements of 0.83 (range 0.78–0.92). Further analyses presented below utilise the average of the three daily FeNO measurements. Sputum samples were obtained and analysed successfully for 39 out of 40 study visits, with 36 of these being spontaneous samples.

In order to assess the relationship between FeNO and recognised biomarkers of eosinophilic airways disease, we constructed a linear mixed model (SPSS 20, IBM Corporation, Somers, New York, NY, USA) in which blood or sputum eosinophil count was the dependent variable and FeNO was specified as a fixed effect in the model. We specified an autoregressive covariance structure for the repeated measures of blood or sputum eosinophil count within each individual, since we observed that repeated measurements became less closely correlated with the passage of time. We performed our analysis using a range of lag periods and windows to determine 1) how changes in FeNO related temporally to changes in blood and sputum eosinophil counts, and 2) whether taking a moving average (window) of 3, 5, 7 or 9 consecutive days' FeNO readings could improve the correlation with blood and sputum eosinophil counts. Figure 1a–b show example data from a single individual, demonstrating the relationship between FeNO and sputum eosinophil count. Increasing the window width results in smoothing of the data, masking day-to-day variability in FeNO and allowing the underlying trends to be better seen.

FIGURE 1
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 1

Relationship between domiciliary exhaled nitric oxide and eosinophilic inflammation. Overlaid time series of exhaled nitric oxide (FeNO) and sputum eosinophil count in one participant, with a FeNO window of a) 1 day and b) 5 days. Colour maps indicating the effect size of FeNO as a predictor of c) sputum eosinophil count and d) blood eosinophil count at a range of lag times and window sizes. A negative lag indicates that FeNO in the present correlates with past blood or sputum eosinophil counts. A positive lag indicates that FeNO in the present correlates with future blood or sputum eosinophil counts.

Figure 1c–d demonstrates colour maps indicating the effect size of FeNO within the model to predict either sputum or blood eosinophil count at different lag periods and window sizes. A higher effect size indicates a stronger association. In these figures, a negative lag indicates that FeNO in the present correlates with past blood or sputum eosinophil counts. A positive lag indicates that FeNO in the present correlates with future blood or sputum eosinophil counts. The association between FeNO and sputum eosinophils was strongest at a lag of -1 and a window of 5, indicating that changes in sputum eosinophils tended to precede changes in FeNO by 1 day. The association between FeNO and blood eosinophils was strongest at a lag of -5 and a window of 7, indicating that changes in blood eosinophils tended to precede changes in FeNO by 5 days.

This is the first study to show that FeNO is a reliable and repeatable method of measuring eosinophilic airway inflammation at home in patients with asthma. Our results indicate that maximal changes in FeNO appear to lag behind changes in sputum and blood eosinophils by 1 and 5 days respectively. However, FeNO can still give a good insight into the current level of sputum eosinophils, particularly if a moving average of 5–7 consecutive days' measurements is used. It should be noted that most patients in this study were able to provide spontaneous sputum samples and did not require formal induction with nebulised hypertonic saline. While spontaneous and induced sputum are not exactly equivalent, previous studies have indicated that the cellular content does not differ significantly between the two methods of expectoration [7].

The home monitoring approach has the advantage of patient convenience, as well as the potential for day-to-day adjustment of therapy or the detection and preventative treatment of incipient asthma exacerbations. Hashimoto et al. [8] recently performed a pragmatic randomised controlled trial in which an internet-based approach to oral corticosteroid tapering, incorporating domiciliary FeNO, was compared to a conventional approach. The internet algorithm was found to allow more rapid tapering of oral corticosteroids without any reduction in asthma control or quality of life. Honkoop et al. [9] found that adjustment of inhaled corticosteroid therapy in primary care using a symptom plus FeNO-driven strategy reduced asthma medication use while sustaining asthma control and quality of life. Malerba et al. [10] found that titrating inhaled corticosteroids using a combination of FeNO and sputum eosinophils reduced exacerbation rates and asthma symptoms compared to a conventional strategy, without additional increases in inhaled corticosteroid doses.

In conclusion, serial FeNO measurements may identify airway inflammation within close temporal proximity to changes in conventional biomarkers of eosinophilic disease such as sputum eosinophil count, with the added value of being of point-of-care. Further prospective trials are required to assess if this approach can successfully predict exacerbations or be used to titrate therapy in adults with asthma.

Footnotes

  • Support statement: This paper presents independent research funded by the National Institute for Health Research (NIHR). The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health. We gratefully acknowledge the loan of NObreath devices from Bedfont Scientific Ltd. Funding information for this article has been deposited with FundRef.

  • Conflict of interest: Disclosures can be found alongside this article at erj.ersjournals.com

  • Received December 8, 2015.
  • Accepted March 4, 2016.
  • Copyright ©ERS 2016

References

  1. ↵
    1. Green RH,
    2. Brightling CE,
    3. McKenna S, et al.
    Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. Lancet 2002; 360: 1715–1721.
    OpenUrlCrossRefPubMedWeb of Science
  2. ↵
    1. Petsky HL,
    2. Cates CJ,
    3. Lasserson TJ, et al.
    A systematic review and meta-analysis: tailoring asthma treatment on eosinophilic markers (exhaled nitric oxide or sputum eosinophils). Thorax 2012; 67: 199–208.
    OpenUrlAbstract/FREE Full Text
  3. ↵
    1. Powell H,
    2. Murphy VE,
    3. Taylor DR, et al.
    Management of asthma in pregnancy guided by measurement of fraction of exhaled nitric oxide: a double-blind, randomised controlled trial. Lancet 2011; 378: 983–990.
    OpenUrlCrossRefPubMed
  4. ↵
    Global Strategy for Asthma Management and Prevention. Global Initiative for Asthma (GINA) 2010. www.ginasthma.org/ Date last updated: May 6, 2015. Date last accessed: December 8, 2015.
  5. ↵
    British Guideline on the Management of Asthma. British Thoracic Society/Scottish Intercollegiate Guidelines Network 2008. www.brit-thoracic.org.uk/guidelines/asthma-guidelines.aspx Date last updated: October 1, 2014. Date last accessed: December 8, 2015.
  6. ↵
    1. Pavord ID,
    2. Pizzichini MM,
    3. Pizzichini E, et al.
    The use of induced sputum to investigate airway inflammation. Thorax 1997; 52: 498–501.
    OpenUrlCrossRefPubMedWeb of Science
  7. ↵
    1. Pizzichini MM,
    2. Popov TA,
    3. Efthimiadis A, et al.
    Spontaneous and induced sputum to measure indices of airway inflammation in asthma. Am J Respir Crit Care Med 1996; 154: 866–869.
    OpenUrlCrossRefPubMedWeb of Science
  8. ↵
    1. Hashimoto S,
    2. Brinke AT,
    3. Roldaan AC, et al.
    Internet-based tapering of oral corticosteroids in severe asthma: a pragmatic randomised controlled trial. Thorax 2011; 66: 514–520.
    OpenUrlAbstract/FREE Full Text
  9. ↵
    1. Honkoop PJ,
    2. Loijmans RJ,
    3. Termeer EH, et al.
    Symptom- and fraction of exhaled nitric oxide-driven strategies for asthma control: A cluster-randomized trial in primary care. J Allergy Clin Immunol 2015; 135: 682–688.
    OpenUrlCrossRef
  10. ↵
    1. Malerba M,
    2. Radaeli A,
    3. Olivini A, et al.
    The combined impact of exhaled nitric oxide and sputum eosinophils monitoring in asthma treatment: a prospective cohort study. Curr Pharm Des 2015; 21: 4752–4762.
    OpenUrlCrossRefPubMed
PreviousNext
Back to top
View this article with LENS
Vol 48 Issue 1 Table of Contents
European Respiratory Journal: 48 (1)
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Domiciliary exhaled nitric oxide and eosinophilic airway inflammation in adults with asthma
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Citation Tools
Domiciliary exhaled nitric oxide and eosinophilic airway inflammation in adults with asthma
Catriona Ruth Nanda, Amisha Singapuri, Marcia Soares, William Monteiro, Salman Siddiqui, Sherif Gonem
European Respiratory Journal Jul 2016, 48 (1) 242-244; DOI: 10.1183/13993003.02060-2015

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Domiciliary exhaled nitric oxide and eosinophilic airway inflammation in adults with asthma
Catriona Ruth Nanda, Amisha Singapuri, Marcia Soares, William Monteiro, Salman Siddiqui, Sherif Gonem
European Respiratory Journal Jul 2016, 48 (1) 242-244; DOI: 10.1183/13993003.02060-2015
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Abstract
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Subjects

  • Asthma and allergy
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

Agora

  • Airway immune responses to COVID-19 vaccination in COPD patients
  • Wider access to rifapentine-based regimens is needed for TB care globally
  • Screening for PVOD in heterozygous EIF2AK4 variant carriers
Show more Agora

Research letters

  • Impact of depression and anxiety on exacerbation risk in bronchiectasis
  • Respiratory management of drowning-associated ARF
  • Mitochondrial DNA as biomarker of survival in RA-ILD
Show more Research letters

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2023 by the European Respiratory Society